Document:

AMENDED
AND RESTATED

    EMPLOYMENT
AGREEMENT

    

    This Amended and Restated Employment
Agreement (the “Agreement”) by and between
Power 3 Medical Products, Inc., a New York corporation (the “Company”), and Ira L.
Goldknopf, Ph.D. (the “Officer”) is executed this 17
day of May, 2009 and shall be effective for all purposes as of May 17, 2009
(the “Effective
Date”).

    

    RECITALS

    

    WHEREAS, the Company and the Officer
previously entered into that certain Employment Agreement dated as of
May 18, 2004 (the “Original
Agreement”);

    

    WHEREAS, the Original Agreement
terminated May 17, 2009; and

    

    WHEREAS, the Company and the Officer
desire to enter into a new Agreement and update the provisions of the Original
Agreement to reflect the parties’ mutual understanding and intent and to restate
the Original Agreement, as amended, in its entirety.

    

    NOW, THEREFORE, in consideration of the
premises and of the covenants and agreements herein provided, the parties hereto
agree as follows:

    

    1.           EMPLOYMENT
TERMS

    

    1.1          Term.  The
Company hereby employs the Officer, and the Officer hereby accepts employment
with the Company, all in accordance with the terms and conditions hereof, for a
term commencing on May 17, 2009 and terminating on May 17,
2012.  However, the Officer shall be considered to be employed by the
Company beyond the Termination Date for purposes of receiving certain benefits
conferred under this Agreement, as described in Paragraph 3.1
hereof.

    

    
      	
               
      

            	
              1.2

            	
              Position and
      Duties.

            

    

    

    (a)            The
Company hereby employs the Officer, and the Officer agrees to serve the Company,
as an Officer of the Company pursuant to the terms of this
Agreement.  The Company has by action of its Board of Directors
appointed the Officer to the position of President and Chief Scientific Officer,
however it may, in the sole and unfettered discretion of the Board of Directors,
amend the Officer’s title and/or duties and responsibilities, provided that the
Officer remains an officer of the Company pursuant to the terms of this
Agreement.

    

    (b)            The
Officer shall be responsible for such duties as are commensurate with the office
in which he serves and as may from time to time be assigned to the Officer by
the Company’s Board of Directors.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              1.3

            	
              Performance of
      Duties.

            

    

    

    (a)            At
all times prior to the Termination Date, the Officer (i) shall devote his full
business time, energies, best efforts, and attention to the business of the
Company, (ii) shall faithfully and diligently perform the duties of his
employment with the Company, (iii) shall do all reasonably in his power to
promote, develop, and extend the business of the Company, and (iv) shall not
enter into the service of, or be employed in any capacity or for any purpose
whatsoever by, any person, firm or corporation other than the Company without
the prior written consent of the Board of Directors of the Company.

    

    (b)            The
Officer shall perform his duties in accordance with all applicable laws, rules,
or regulations that apply to the Company and/or its business, assets (real or
personal), or employees.

    

    2.            COMPENSATION.

    

    2.1           Salary.

    

    (a)           For
so long as Officer is employed by the Company, the Company agrees to pay to the
Officer, and the Officer shall accept from the Company, for all of his services
rendered pursuant to this Agreement, a salary of One Hundred  Thousand
Dollars ($100,000) per annum, payable semimonthly prorated for the period from
May 18, 2009 to May 31, 2009, and a salary of One Hundred Twenty-Five Thousand
Dollars ($125,000) per annum, payable semimonthly for the period beginning June
1, 2009.

    

    (b)           The
Company’s Board of Directors, or compensation committee of the Board of
Directors (the “Compensation
Committee”), shall review the Officer’s salary annually and merit
increases thereon shall be considered and may be approved, in the sole and
unlimited discretion of the Company’s Board of Directors, depending in part on
the profits and cash flow of the Company.  If the Company’s Board of
Directors elects in its discretion to increase the salary of the Officer at any
time or from time to time, the new salary rate shall, without further action by
the Officer or the Company, be deemed substituted for the amount set forth
above.  At such time, this Agreement shall be deemed amended
accordingly (notwithstanding the provisions of Paragraph 7.8 below), and, as so
amended, shall remain in full force and effect.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    2.2           Bonuses.           The
Company shall award the Officer a bonus of One Thousand Dollars ($1,000) for
each publication authored by the Officer, or co-authored with another
collaborator, which is published in a scientific or professional journal, in
which the publication enhances the Company’s intellectual property, the
Company’s scientific discoveries, the Company’s diagnostic testing products, or
the Company’s overall visibility in its marketing efforts. The Company, in the
sole and unfettered discretion of its Board of Directors or Compensation
Committee, may from time to time award additional cash bonuses to the Officer
based upon its measure of Officer’s performance.  Such bonuses may be
awarded in a lump sum or may be conditioned upon the future performance or
employment of Officer, in the sole and unfettered discretion of the Board of
Directors of the Company.

    

    2.3           Expenses.         Upon
submission of appropriate invoices or vouchers, the Company shall pay or
reimburse the Officer for all reasonable expenses incurred by the Officer in the
performance of his duties hereunder in furtherance of the business of the
Company.

    

    2.4           Benefits.           The
Company extends to the Officer the right to participate in whatever employee
benefit plans (excluding any employee benefit plan covered separately in this
Agreement) may be in effect from time to time, to the extent the Officer is
eligible under the terms of the plans.  However, no employee benefits
other than those specifically conferred by the terms of this Agreement have been
promised to the Officer in connection with this employment.  The
adoption of one or more employee benefit plans, the terms of the plans, and the
Officer’s participation in the plans, if any, are in the sole discretion of the
Company and may be changed by the Company at any time and from time to
time.

    

    2.5           Stock
Grant.

    

    (a)           Over
the period of The Original Agreement, the Officer was granted by the Company
restricted common shares of the Company’s stock (the “Common Shares”) and One
Million Five Hundred (1,500,000) shares of Series B preferred stock to be
designated by the Company (the “Series B Shares”); and
collectively with the Common Shares, the “Restricted Stock”. The grant
of the Restricted Stock shall continue to be subject to the following terms and
conditions:

    

    (i)           Until
such time as the restricted stock becomes non-forfeitable, the Company retains
the right, at the discretion of the Board of Directors, to use any of such
shares as deemed necessary, solely to pledge as collateral to raise funds for
the benefit of the company. In the event that such shares become forfeit of a
pledge, the company may at the discretion of the board of directors issue
replacement shares to the employee under the restrictions of this agreement.
During the course of the pledge, the voting rights of the pledged shares remain
with the employee.

    

    (ii)          Upon
issuance of the Restricted Stock, except for the restrictions set forth in this
Paragraph 2.5, the Officer shall have all rights of a shareholder of the
Company with respect to such Restricted Stock including the right to vote such
Restricted Stock and to receive all dividends and other distributions paid with
respect to such Restricted Stock; provided, however, dividends, if any, paid or
distributed on the Restricted Stock shall not be paid by the Company to the
Officer unless and until such time as the Restricted Stock becomes
non-forfeitable.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    (iii)         
In the event of a Change in Control (as herein defined), the Company waives in
whole or in part any and all remaining restrictions on the Restricted
Stock.  For purposes hereof, a Change of Control shall mean, and shall
be deemed to have occurred:

    

    (A)           if
any person, other than any benefit plan of the Company or the Officer, as holder
of the Series B Preferred Stock, directly or indirectly, becomes the
beneficial owner (as defined in Section 13(d) of the Securities Exchange
Act of 1934, as amended) of securities representing 51% or more of the combined
voting power of the Company’s then-outstanding securities, but excluding any
such acquisition pursuant to a merger, consolidation or similar business
combination involving the Company; or

    

    (B)           upon
the consummation of a merger, consolidation, or similar business combination
involving the Company, other than any such transaction which results in at least
75% of the total voting power represented by the voting securities of the
surviving entity (or the parent entity thereof) outstanding immediately after
such transaction being beneficially owned by at least 75% of the holders of the
outstanding voting securities of the Company immediately prior to the
transaction with the voting power of each such continuing holder relative to
other such continuing holders not being substantially altered in the
transaction; or

    

    (C)           upon
the Board of Directors or the shareholders of the Company approving a plan of
complete or substantially complete liquidation of the Company; or

    

    (D)           upon
the consummation of the sale, lease, or disposition by the Company of 50% or
more of the total assets of the Company in one or a series of related
transactions (provided that a license, sublicense or similar transaction
involving the Company’s intellectual property rights shall not be considered as
a Change of Control); or

    

    (E)           upon
the individuals who constitute the Board as of the Effective Date (the “Incumbent Board”) ceasing for
any reason to constitute at least a majority of the members of the Board,
provided that any person becoming a director after the Effective Date whose
election, or nomination for election by the Company’s shareholders, was approved
by a vote of at least two-thirds of the directors then comprising the Incumbent
Board (other than any individual whose initial assumption of office occurs as a
result of either (a) an actual or threatened election contest or
(b) an actual or threatened solicitation of proxies or consents by or on
behalf of a person other than the Board) shall be, for purposes of this
Agreement, considered as though such person were a member of the Incumbent
Board.

    

    (v)          The
Common Shares shall have demand registration rights or piggyback registration
rights (neither of which, however, shall be effective unless and until the
Officer’s rights to such shares have ceased to be subject to the risks of
forfeiture as provided herein).

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    (b)           The
Officer agrees to pay in a timely manner deemed suitable by the Company, and to
indemnify and hold harmless the Company from, any and all taxes (including all
penalties and interest, if any, thereon), resulting from the grant and/or
transfer of the above-referenced Restricted Stock for which ultimate
responsibility is assigned to or asserted against the Officer under applicable
law.  For purposes of this provision, all withholding obligations of
the Company in respect of the aforementioned taxes (including any and all taxes,
penalties and interest imposed on or asserted against the Company for failure to
properly withhold and remit any such amounts in a timely manner) shall be
considered the responsibility of the Officer and, accordingly, the Officer
agrees to pay in a timely manner deemed suitable by the Company, and to
indemnify and hold harmless the Company from, any and all of such
obligations.

    

    2.6           Vacation; Sick
Leave.    The Company’s vacation and sick leave policy has
been established by the Company and may be changed by the Company at any time
and from time to time.  Said policy is published in separate data
files accessible to the Officer.  The Officer will not be entitled to
receive payment for any unused sick leave either during employment or upon
termination of employment.

    

    2.7           Withholding.      The
Company may withhold from any amounts payable under this Agreement any and all
federal, state, city, or other taxes or other amounts required to be withheld by
any applicable law.

    

    3.            TERMINATION.

    

    3.1           Termination Upon 30 Days
Notice.

    

    (a)           Either
party may terminate the Officer’s employment under this Agreement for any reason
whatsoever, either with or without cause, upon giving the other party no less
than thirty (30) days prior written notice of such termination ( the “Notice Date”).  The
effective date of a termination pursuant to this Paragraph 3.1 shall be such
termination date as stated on the notice, provided that the termination date can
be no earlier than the 31st day
following the day the notice becomes effective pursuant to Paragraph 5.4 below
(the “Termination
Date”).

    

    (b)           Until
the expiration of the contract on May 17, 2012 (“Transition Period”), unless
terminated for “Cause” as defined in Paragraph 3.4 or if the Officer
resigns from his position or duties, the Officer will continue to be considered
as an employee of the Company only for the purpose of receiving the compensation
and benefits awarded in Paragraphs 2.1, 2.2, and 2.4
hereof.  More specifically, for the duration of Transition Period the
Officer (i) shall continue to receive his salary at the rate in effect as of the
Notice Date, (ii) shall continue to be considered an employee of the Company for
purposes of determining eligibility to receive any contingent or deferred
bonuses awarded to the Officer prior to the Termination Date, (iii) shall
continue to be considered an officer of the Company for purposes of vesting in
any stock options granted to Officer (but not for purposes of the forfeiture
restrictions applicable to the Restricted Stock as set forth in
Paragraph 2.5), and (iv) shall, to the extent allowed by such plan, remain
eligible to participate in any benefit plan of the Company in which the Officer
participates as of the Notice Date.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    (c)           Notwithstanding
any provision herein to the contrary, however, the Officer will not be entitled
to act as, or represent himself to be, an officer or employee of the Company
following the Termination date and will not be entitled to receive or
participate in any bonus, incentive, or benefit program, involving stock or
otherwise, that is established following the Termination Date.

    

    3.2           Termination by Mutual
Consent.   The Officer and the Company may at any time
terminate the employment of the Officer under this Agreement by mutual consent
in writing upon the terms and conditions stated in such writing.

    

    3.3           Termination Upon
Death.   If the Officer dies, his employment shall immediately
terminate automatically as of the date of his death.  In such event,
the Officer shall be treated as if he had terminated his employment with the
Company under the terms of Paragraph 3.1 above, with the date of his death
serving as both the Notice Date and the Termination Date.

    

    3.4           Termination for
Cause.   This Agreement may be terminated for Cause by either
party for the following reasons, only:

    

    

    3.4.a.1  Commission of a
criminal offense by either party in the course of performance of the Agreement
shall entitle the other to effect immediate termination upon giving written
notice;

    

    3.4.a.2  If either
party becomes insolvent or makes a general assignment for the benefit of
creditors or if petition in bankruptcy is filed against the defaulting party and
is not discharged or disputed within five (5) working days of such filing or of
the agent is adjudicated bankrupt or insolvent;

    

    3.4.a.3  The election of
one party (the “aggrieved
party”) to terminate this Agreement upon (1) the actual breach or actual
default by the other party in the reasonable performance of the defaulting
party’s obligations and duties under this Agreement and (2) the failure of the
defaulting party to cure the same within fifteen (15) days (the “cure period”)
after receipt by the defaulting party of a good faith written notice from the
aggrieved party specifying such breach or default and (3) provided that the
defaulting party has not cured the default and the aggrieved party may then give
written notice to defaulting party of his or its election to terminate ten (10)
days after expiration of the cure period.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    3.5           Transition.  Officer
shall make a good faith effort to aid in the transition of management
necessitated by the termination of his employment pursuant to this
Agreement.  To the extent feasible and/or practical, Officer shall
devote the time and energy necessary to effect said goal of a smooth transition
for the successor chief scientific officer.  The salary payable to
Officer by the Company pursuant to Paragraph 2.1(a) of this contract shall
continue to be paid to Officer during such transition period.

    

    4.           PROPRIETARY INFORMATION AND
ITEMS.

    

    4.1           Acknowledgments.    The
Officer acknowledges that (a) the Officer has or will be afforded access to
Proprietary Information of the Company or its affiliates; (b) public disclosure
of such Proprietary Information could have an adverse effect on the Company and
its affiliates; and (c) the provisions of this Section 4 are reasonable and
necessary to prevent the improper use or disclosure of such Proprietary
Information.

    

    4.2           Non-Disclosure and Non-Use
of Proprietary Information.     During the Officer’s
employment by the Company and for a period of five (5) years thereafter, the
Officer covenants and agrees that the Officer (a) shall not disclose to others
or use for the benefit of himself or others, any of the Company’s Proprietary
Information, except that the Officer may disclose such information (i) in the
course of and in furtherance of the Officer’s employment with the Company to the
extent necessary for the benefit of the Company, (ii) with the prior specific
written consent of the Board of Directors of the Company, or (iii) to the extent
required by law; and (b) shall take all measures reasonably necessary to
preserve the confidentiality of all Proprietary Information of the Company known
to the Officer, shall cooperate fully with the Company’s or its affiliates’
enforcement of measures intended to preserve the confidentiality of all
Proprietary Information, and shall notify the Board of Directors immediately
upon receiving any request for, or making any disclosure of, any Proprietary
Information from or to any person other than an officer or employee of the
Company or of one of its affiliates who has a need to know such
information.

    

    4.3           Proprietary
Information.  For purposes of this Agreement,  “Proprietary Information”
means trade secrets, secret or confidential information or knowledge pertaining
to, or any other nonpublic information pertaining to the business or affairs of
the Company or any of its affiliates, including without limitation, medical
imaging software programs (including source code and object code) and design
documentation; identities, addresses, backgrounds, or other information
regarding licensors, suppliers, customers, sublicenses, potential customers and
sublicenses, employees, contractors, or sources of referral; marketing plans or
strategies, business or personnel acquisition plans; pending or contemplated
projects, ventures, or proposals; financial information (including historical
financial statements; financial, capital, or operating budgets, plans or
projections; historical or projected sales, royalties and license fees, and the
amounts of compensation paid to employees and contractors); trade secrets,
know-how, technical processes, or research projects; and notes, analysis,
compilations, studies, summaries, and other material prepared by or for the
Company containing or based, in whole or in part, on any information included in
the foregoing, except information that is generally known in the industry (other
than as a result of a disclosure by the Officer).

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    4.4           Proprietary
Items.   Upon termination or expiration of the Officer’s
employment by the Company for any reason or by either party, or upon the request
of the Company during such tenure, the Officer will immediately return to the
Company all Proprietary Items in the Officer’s possession or subject to the
Officer’s control, and the Officer shall not retain any copies, abstracts,
sketches, or other physical embodiment of any Proprietary Items.  For
purposes of this Agreement, “Proprietary
Items” means all
documents and tangible items (including all customer lists, memoranda, books,
papers, records, notebooks, plans, models, components, devices, or computer
software or code, whether embodied in a disk or in any other form) provided to
the Officer by the Company, created by the Officer, or otherwise coming into the
Officer’s possession for use in connection with is engagement with the Company
or otherwise containing Proprietary Information (whether provided or created
during the term of this agreement or prior thereto).

    

    4.5           Ownership
Rights.  The Officer recognizes that, as between the Company
and the Officer, all of the Proprietary Information and all of the Proprietary
Items, whether or not developed by the Officer, are the exclusive property of
the Company.  The Officer agrees that all intellectual property of
every kind, including without limitation copyright, patent, trademarks, trade
secrets, and similar rights, created or developed or realized in connection with
the Officer’s performance of any duties or functions as an Officer of the
Company (collectively, the “Intellectual Property”) shall
be the exclusive property of the Company and shall constitute Proprietary
Information.  The Officer hereby assigns unto the Company all rights,
title, and interest that the Officer may have to such Intellectual Property and
each and every derivative work thereof, and agrees to execute, acknowledge, and
deliver to the Company as assignment to the Company of any right, title, or
interest of the Officer in any and all such Intellectual Property, in such form
as may be reasonably requested by the Company.

    

    4.6           Disputes of
Controversies.  The Officer recognizes that, should a dispute or
controversy arising from or relating to this portion of the Agreement (Section
4) be submitted for adjudication to any court, arbitration panel, or other third
party, the preservation of the secrecy of Proprietary Information may be
jeopardized.  The Officer agrees that he will use best efforts to
ensure that all pleadings, documents, testimony, and records relating to any
such adjudication will be maintained in secrecy.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    5.           NON-INTERFERENCE; COMPLIANCE
WITH LAW; COOPERATION

    

    5.1           Non-Interference.    During
the Officer’s employment with the Company and for a period of five (5) years
following termination or expiration of such tenure, the Officer covenants and
agrees that the Officer shall not, directly or indirectly, for the benefit of
the Officer or another (a) persuade or attempt to persuade any employee,
independent contractor, consultant, agent, supplier, licensor, or distributor of
the Company or of any affiliate of the Company to discontinue such person’s
relationship with the Company or the affiliate; (b) hire away or solicit to hire
away from the Company or from any of its affiliates any employee; (c) otherwise
engage or seek to engage any employee or independent contractor of the Company
or of any of its affiliates in a business relationship that would or might
conflict with such employee’s or independent contractor’s obligations to the
Company or affiliate; (d) interfere with the Company’s or any of its affiliates’
relationship with any governmental or business entity, including payor,
supplier, licensor, lender, or contractor of the Company or the affiliate; or
(e) disparage the Company or any of its affiliates or any of the shareholders,
directors, officers, employees, or agents of any of them.

    

    5.2           Cooperation.  
During the Officer’s Employment with the Company and for a period of five (5)
years following the termination or expiration of such tenure, the Officer agrees
to cooperate with the Company and its affiliates in connection with any
litigation or investigation involving the Company or any of its affiliates or
any of the shareholders, directors, officers, employees, or agents of any of
them and shall furnish such information and assistance as may be lawfully
requested by the Company.

    

    6.           NON-COMPETITION

    

    During the Officer’s employment by the
Company and for a period of two (2) years following the termination or
expiration of such tenure, the officer covenants and agrees to refrain from
carrying on or engaging in a business similar to that of the Company, and from
soliciting customers of the Company, within the North America, so long as the
Company carries on a like business therein.  It is further stipulated
that as forbearance for this contract term, Company has provided Officer with
separate and distinct consideration consisting of 25,000 shares of common
stock.  Such shares are included in the Common Shares described in
Paragraph 2.5 and shall be subject to the restrictions set forth
therein.

    

    Each word
of the foregoing provision is severable.

    

    7.           GENERAL
PROVISIONS

    

    7.1           Indemnification.   The
Company hereby agrees to indemnify and hold harmless the Officer from and
against any and all losses, claims, damages, expenses and/or liabilities which
may incur arising out of the normal course of business in carrying out the
duties and responsibilities associated with the position of Chief Scientific
Officer arising from the Officer’s reliance upon and approved use of
information, reports and data furnished by and representations made by the
Company, with respect to itself, where the Officer in turn distributes and
conveys such information, reports and data to the public in the normal course of
representing the Company.  Such indemnification shall include, but not
be limited to, expenses (including all attorneys’ fees), judgments, and amounts
paid in settlement actually and reasonably incurred by Officer in connection
with an action, suit or proceeding brought against the Company or
Officer.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    7.2           Injunctive
Relief.      The Officer acknowledges that
the injury that would be suffered by the Company as a result of a breach of the
provisions of this Agreement would be largely irreparable and that an award of
monetary damages to the Company for such a breach would be an inadequate
remedy.  The Company will have the right, in addition to any other
rights it may have (including the right to damages that the Company may suffer),
to obtain injunctive relief to restrain any breach or threatened breach or
otherwise to specifically enforce any provision of this Agreement, and the
Company will not be obligated to post bond or other security in seeking such
relief.  The Officer agrees to request neither bond nor security in
connection with any such injunction.  The Officer agrees that if he
breaches this Agreement, the Officer shall be liable for any attorney’s fees and
costs incurred by the Company in enforcing its rights under this
Agreement.

    

    7.3           Essential, Independent, and
Surviving Covenants.

    

    (a)           The
parties agree that the covenants by the Officer in Sections 4, 5, and 6 are
essential elements of this Agreement, and without the Officer’s agreement to
comply with such covenants, the Company would not have entered into this
Agreement.

    

    (b)           The
Officer’s covenants in Sections 4, 5, and 6 are independent covenants and the
existence of any claim by the officer against the Company under this Agreement
or otherwise will not excuse the Officer’s breach of any covenant in Section 4,
5, or 6.

    

    (c)           After
the Officer’s employment by the Company is terminated, this Agreement will
continue in full force and effect as is necessary or appropriate to enforce the
covenants and agreements of the Officer in Sections 4, 5, and 6.

    

    7.4           Binding Effect; Benefits;
Assignment.    This Agreement shall inure to the
benefit of, and shall be binding upon, the parties hereto and their respective
successors, assigns, heirs, and legal representatives.  Insofar as the
Officer is concerned, this contract, being personal, cannot be assigned other
than by will or the laws of descent and distribution.

    

    7.5           Notices.  All
notices and other communications which are required or permitted hereunder shall
be in writing and shall be sufficient if mailed by certified mail, postage
prepaid, and shall be effective three days after such mailing or upon delivery,
whichever is earlier, to the following addresses or such other address as the
appropriate party may advise each other party hereto:

    

    If to the Officer:

    

    Ira L. Goldknopf,
Ph.D.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    42 Bushwood Court

    The Woodlands, TX 77380

    

    If to the Company:

    Power 3 Medical Products,
Inc.

    3400 Research Forest
Drive

    The Woodlands,
TX  77381

    

    Copy to:

    

    Billings and Solomon,
PLLC

    
      	
               
      

            	
              2777
      Allen Parkway, Suite 460

            

    

    Houston, TX 77019

    ATTN:  Richard P.
Martini

    

    7.6           Entire
Agreement.     This Agreement contains the
entire agreement between the parties hereto and supersedes all prior agreements
and understandings, oral or written, between the parties hereto with respect to
the subject matter hereof including, without limitation, the Original
Agreement.

    

    7.7           No Third-Party
Beneficiaries.   This Agreement shall not confer any rights or
remedies upon any person other than the Company, the Officer, and their
respective successors and permitted assigns, other than as expressly set forth
in this Agreement.

    

    7.8           Amendments and
Waivers.      Except as set forth in
Paragraph 2.1(b) above, this Agreement may not be modified or amended except by
an instrument or instruments in writing signed by the party against whom
enforcement of any such modification or amendment sought.  Either
party hereto may, by an instrument in writing, waive compliance by the other
party with any term or provision of this Agreement on the part of such other
party hereto to be performed or complied with.  The waiver by any
party hereto of a breach of any term or provision of this Agreement shall not be
construed as a waiver of any subsequent breach.  No delay or failure
by either party in exercising any right under this Agreement, and no partial or
single exercise of that right, shall constitute a waiver of that or any other
right.

    

    7.9           Headings.  The
paragraph headings contained in this Agreement are for reference purposes only
and shall not be deemed to be a part of this Agreement or to control or affect
the meaning or construction of any provision of this Agreement.

    

    7.10         Construction.   
The language used in this Agreement will be deemed to be the language chosen by
the Company and the Officer to express their mutual intent, and no rule of
strict construction shall be applied against either party.

    

    7.11         Counterparts.  This
Agreement may be executed in two or more counterparts, each of which shall be
deemed an original but all of which together shall constitute one and the same
instrument.

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    7.12        Severability.     If
any term or provision of this Agreement is held or deemed to be invalid or
unenforceable, in whole or in part, by a court of competent jurisdiction, this
Agreement shall be ineffective to the extent of such invalidity or
unenforceability without rendering invalid or unenforceable the remaining terms
and provisions of this Agreement.

    

    7.13        Expenses and Attorney’s
Fees.   In the event that a dispute arises under this Agreement
that results in litigation or arbitration, the prevailing party, as determined
by the decision of a court or forum of competent and final jurisdiction, shall
be entitled to court costs and reasonable attorney’s fees.  A court or
forum of “final” jurisdiction shall mean a court of forum from which no appeal
may be taken or from whose decree, decision, judgment, or order no appeal is
taken or prosecuted.

    

    7.14        Governing
Law.   This Agreement shall be governed by and construed in
accordance with the laws of the State of Texas, without regard to the conflict
of laws principles thereof.

    

    7.15        Agreement
Preparation.  The Officer acknowledges that this Agreement has been
prepared by counsel for the Company, and the Officer has not relied on any
representation made by the Company’s attorneys.  The Officer has
engaged an attorney of his choice to review this agreement on his
behalf.  By signing this employment agreement, officer is hereby
certifying that officer (a) received a copy of this agreement for review and
study before executing it; (b) read this agreement carefully before signing it;
(c) had sufficient opportunity before signing the agreement to ask any questions
officer had about the agreement and received satisfactory answers to all such
questions; and (d) understands officer’s rights and obligations under the
agreement.

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, the parties
hereto have duly executed this Employment Agreement as of the date first written
above but to be effective as of the Effective Date.

    

    
      
        
          
            
              
                	 
      	
                        OFFICER:

                      
	 
      	 
      
	 
      	
                        /s/ Ira L. Goldknopf_

                      
	 
      	
                        Ira
      L. Goldknopf, Ph.D.

                      
	 
      	 
      
	 
      	
                        COMPANY:

                      
	 
      	 
      
	 
      	
                        Power
      3 Medical Products, Inc.

                      
	 
      	 
      
	 
      	
                        By:

                      	
                        /s/ Helen R. Park

                      
	 
      	 	
                           
      Helen R. Park

                      
	 
      	 	
                           
      Interim Chief Executive
Officer

                      

              

            

          

        

      

    

    
      
         

      

      
        13AMENDED
AND RESTATED

    CONSULTING
AGREEMENT

    

    This Amended and Restated Consulting
Agreement (the “Agreement”) by and between
Power 3 Medical Products, Inc., a New York corporation (the “Company”), and Bronco
Technology, Inc. (“BTI”)
is executed the 1 day of June, 2009 and shall be effective for all purposes as
of June 1, 2009 (the “Effective
Date”).

    

    RECITALS

    

    WHEREAS, the Company and BTI previously
entered into that certain Consulting Agreement dated as of September 7, 2008
(the “Original
Agreement”);

    

    WHEREAS, the Company is contracting to
receive the services of Helen R. Park, CEO of BTI (the “Officer”), as Interim CEO of
Power3 Medical Products, Inc.

    

    WHEREAS, the Officer has a background
in biotechnology business consulting, planning, and reorganization and is
willing to provide services to the Company through BTI based on this
background.

    

    WHEREAS, the Company and BTI desire to
amend the Original Agreement and update the provisions of the Original Agreement
to reflect the parties’ mutual understanding and intent and to restate the
Original Agreement, as amended, in its entirety.

    

    NOW, THEREFORE, in consideration of the
premises and of the covenants and agreements herein provided, the parties hereto
agree as follows:

    

    1.       
    CONSULTING
TERMS

    

    1.1           Term.  The
Company hereby contracts with BTI for the Officer to serve as Interim Chief
Executive Officer, and BTI on behalf of the Officer hereby accepts to serve as
Interim Chief Executive Officer with the Company, all in accordance with the
terms and conditions hereof, for a term commencing on June 1, 2009 and
terminating on May 31, 2011.

    

    
      1.2          
Position and
Duties.

    

    

    (a)            The
Company has by action of its Board of Directors appointed the Officer to the
position of Interim Chief Executive Officer, reporting to the Board of Directors
of the Company, on a consulting basis.

    

    (b)            The
Officer shall be responsible for such duties including, but not limited to,
management, business planning, and marketing services.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      1.3         
 Performance of
Duties.

    

    

    (a)            At
all times prior to the Termination Date, the Officer (i) shall devote her full
business time, energies, best efforts, and attention to the business of the
Company, (ii) shall faithfully and diligently perform the duties of her
responsibilities with the Company, and (iii) shall do all reasonably in her
power to promote, develop, and extend the business of the Company.

    

    (b)           The
Officer shall perform her duties in accordance with all applicable laws, rules,
or regulations that apply to the Company and/or its business, assets (real or
personal), or employees.

    

    (c)           During
the term of the Agreement, the Company shall provide the support services to the
Officer, including office space, use of staff and administrative support, and
office supplies.

    

    1.4           Relationship of
Parties.  The Company and BTI mutually understand that BTI and
the Officer are independent contractors with respect to the Company, and are not
employees of the Company.  The Company, will not provide fringe
benefits, including health insurance benefits, paid vacation, or any other
employee benefit, for the benefit of BTI or the Officer.

    

    2. 
          COMPENSATION.

    

    2.1           Monthly Services
Payment.

    

    (a)           For
so long as the Officer is providing services to the Company, the Company agrees
to pay to BTI, and BTI shall accept from the Company, for all of the services
rendered by the Officer pursuant to the Agreement, a compensation payment of
Eight Thousand Three Hundred Thirty-Four Dollars ($8,334) per month, payable on
the last day of each month that services are performed.

    

    (b)           The
Company’s Board of Directors, or compensation committee of the Board of
Directors (the “Compensation
Committee”), shall review BTI’s compensation annually and compensation
increases thereon shall be considered and may be approved, in the sole and
unlimited discretion of the Company’s Board of Directors, depending in part on
the profits and cash flow of the Company.  If the Company’s Board of
Directors elects in its discretion to increase the compensation of BTI at any
time or from time to time, the new compensation rate shall, without further
action by BTI or the Company, be deemed substituted for the amount set forth
above.  At such time, the Agreement shall be deemed amended
accordingly (notwithstanding the provisions of Paragraph 7.8 below), and, as so
amended, shall remain in full force and effect.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    2.2           Commission
Payments.   The Company shall award BTI a monthly
commission of 1% payment, not to exceed Five Thousand ($5,000) per month, of the
royalties recognized and earned by the Company from the sale of its NuroPro and
BC SeraPro diagnostic testing products through license agreements signed during
the term of the Agreement.

    

    (a)           The
Company shall pay commission payments to BTI no later than 30 days after the
Company recognizes and earns royalty revenues through the license
agreements.

    

    (b)           The
Company shall maintain records in sufficient detail for purposes of determining
the amount of commission.  The Company shall provide to BTI a written
accounting that sets forth the manner in which the commission payment was
calculated.

    

    (c)           BTI,
or BTI’s agent, shall have the right to inspect the Company’s records for the
limited purpose of verifying the calculation of the commission payments, subject
to such restrictions as the Company may reasonably impose to protect the
confidentiality of the records.  Such inspections shall be made during
reasonable business hours as may be set by the Company.

    

    (d)           If
the Officer dies or becomes disabled and unable to perform the services as
Interim Chief Executive Officer during the term of this Agreement, BTI shall be
entitled to commission payments for the remainder of the term of the
Agreement.

    

    2.3            Bonuses.  The
Company, in the sole and unfettered discretion of its Board of Directors or
Compensation Committee, may from time to time award additional cash bonuses to
BTI based upon its measure of the Officer’s performance.  Such bonuses
may be awarded in a lump sum or may be conditioned upon the future
performance

    

    2.4           Expenses.  Upon
submission of appropriate invoices or vouchers, the Company shall pay or
reimburse the Officer for all reasonable expenses incurred by the Officer in the
performance of her duties hereunder in furtherance of the business of the
Company.

    

    3.         
   TERMINATION.

    

    3.1           Termination Upon 30 Days
Notice.

    

    (a)           Either
party may terminate the Officer’s Agreement for any reason whatsoever, either
with or without cause, upon giving the other party no less than thirty (30) days
prior written notice of such termination (the “Notice Date”).  The
effective date of a termination pursuant to this Paragraph 3.1 shall be such
termination date as stated on the notice, provided that the termination date can
be no earlier than the 31st day
following the day the notice becomes effective pursuant to Paragraph 5.4 below
(the “Termination
Date”).

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    3.2           Termination by Mutual
Consent.  BTI and the Company may at any time terminate the
Agreement by mutual consent in writing upon the terms and conditions stated in
such writing.

    

    3.3           Termination Upon
Death.   If the Officer dies or becomes disabled, the
Agreement shall immediately terminate automatically as of the date of her death
or disability.  In such event, the Agreement shall be treated as if it
had terminated under the terms of Paragraph 3.1 above, with the date of the
Officer’s death or disability serving as both the Notice Date and the
Termination Date.

    

    3.4           Transition.  BTI
and the Officer shall make a good faith effort to aid the Company in the
transition of management necessitated by the termination of the
Agreement.  To the extent feasible and/or practical, the Officer shall
devote the time and energy necessary to effect said goal of a smooth transition
for the successor chief executive officer.  The compensation payable
to BTI by the Company pursuant to Paragraph 2.1(a) of this contract shall
continue to be paid to BTI during such transition period.

    

    
      4.           
DISCLOSURE

    

    

    4.1           Disclosure.      BTI
is required to disclose any outside activities or interest, including ownership
or participation in the development of prior invention, that conflict or may
conflict with the best interest of the Company.  Prompt disclosure is
required if the activity or interest is related, directly or indirectly, to: any
intellectual property of the Company; a product or product line of the Company;
a manufacturing process of the Company; or any activity that BTI may be involved
with on behalf of the Company.

    

    4.2           Employees of
BTI.    BTI employees, if any, who perform services
for the Company under this Agreement, and the Officer, shall also be bound by
the provision of this Agreement.

    

    5.         
   PROPRIETARY INFORMATION AND
ITEMS.

    

    5.1           Acknowledgments.  BTI
acknowledges that (a) the Officer has or will be afforded access to Proprietary
Information of the Company or its affiliates; (b) public disclosure of such
Proprietary Information could have an adverse effect on the Company and its
affiliates; and (c) the provisions of this Section 5 are reasonable and
necessary to prevent the improper use or disclosure of such Proprietary
Information.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    5.2           Non-Disclosure and Non-Use
of Proprietary Information.During the term of this Agreement and for a
period of five (5) years thereafter, BTI covenants and agrees that BTI and the
Officer (a) shall not disclose to others or use for the benefit of themselves or
others, any of the Company’s Proprietary Information, except that BTI or the
Officer may disclose such information (i) in the course of and in furtherance of
the services with the Company to the extent necessary for the benefit of the
Company, (ii) with the prior specific written consent of the Board of Directors
of the Company, or (iii) to the extent required by law; and (b) shall take all
measures reasonably necessary to preserve the confidentiality of all Proprietary
Information of the Company known to BTI and the Officer, shall cooperate fully
with the Company’s or its affiliates’ enforcement of measures intended to
preserve the confidentiality of all Proprietary Information, and shall notify
the Board of Directors immediately upon receiving any request for, or making any
disclosure of, any Proprietary Information from or to any person other than an
officer or employee of the Company or of one of its affiliates who has a need to
know such information.

    

    5.3           Proprietary
Information.  For purposes of this Agreement,  “Proprietary Information”
means trade secrets, secret or confidential information or knowledge pertaining
to, or any other nonpublic information pertaining to the business or affairs of
the Company or any of its affiliates, including without limitation, medical
imaging software programs (including source code and object code) and design
documentation; identities, addresses, backgrounds, or other information
regarding licensors, suppliers, customers, sublicenses, potential customers and
sublicenses, employees, contractors, or sources of referral; marketing plans or
strategies, business or personnel acquisition plans; pending or contemplated
projects, ventures, or proposals; financial information (including historical
financial statements; financial, capital, or operating budgets, plans or
projections; historical or projected sales, royalties and license fees, and the
amounts of compensation paid to employees and contractors); trade secrets,
know-how, technical processes, or research projects; and notes, analysis,
compilations, studies, summaries, and other material prepared by or for the
Company containing or based, in whole or in part, on any information included in
the foregoing, except information that is generally known in the industry (other
than as a result of a disclosure by BTI or the Officer).

    

    5.4           Proprietary
Items.   Upon termination or expiration of the Agreement
for any reason, BTI and the Officer will immediately return to the Company all
Proprietary Items in BTI’s or the Officer’s possession or subject to BTI’s or
the Officer’s control, and BTI and the Officer shall not retain any copies,
abstracts, sketches, or other physical embodiment of any Proprietary
Items.  For purposes of this Agreement, “Proprietary
Items” means all
documents and tangible items (including all customer lists, memoranda, books,
papers, records, notebooks, plans, models, components, devices, or computer
software or code, whether embodied in a disk or in any other form) provided to
BTI or the Officer by the Company, created by BTI or the Officer, or otherwise
coming into BTI’s or the Officer’s possession for use in connection with the
engagement with the Company or otherwise containing Proprietary Information
(whether provided or created during the term of this agreement or prior
thereto).

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    5.5           Ownership
Rights.  BTI and the Officer recognizes that, as between the
Company and BTI and the Officer, all of the Proprietary Information and all of
the Proprietary Items, whether or not developed by the Officer, are the
exclusive property of the Company.  BTI and the Officer agree that all
intellectual property of every kind, including without limitation copyright,
patent, trademarks, trade secrets, and similar rights, created or developed or
realized in connection with the Officer’s performance of any duties or functions
as an officer of the Company (collectively, the “Intellectual Property”) shall
be the exclusive property of the Company and shall constitute Proprietary
Information.  BTI hereby assigns unto the Company all rights, title,
and interest that BTI may have to such Intellectual Property and each and every
derivative work thereof, and agrees to execute, acknowledge, and deliver, and
cause the Officer to execute, acknowledge and deliver, to the Company an
assignment to the Company of any right, title, or interest of BTI and the
Officer in any and all such Intellectual Property, in such form as may be
reasonably requested by the Company.

    

    5.6           Disputes of
Controversies.   BTI recognizes that, should a dispute or
controversy arising from or relating to a portion of the Agreement (Section 5)
be submitted for adjudication to any court, arbitration panel, or other third
party, the preservation of the secrecy of Proprietary Information may be
jeopardized.  BTI agrees that it will use its best efforts to ensure
that all pleadings, documents, testimony, and records relating to any such
adjudication will be maintained in secrecy.

    

    6.  
         NON-INTERFERENCE; COMPLIANCE
WITH LAW; COOPERATION

    

    6.1           Non-Interference.  
During the term of the Agreement and for a period of five (5) years following
termination or expiration of the Agreement, BTI covenants and agrees that BTI
shall not, directly or indirectly (including through the Officer), for the
benefit of BTI or another (a) persuade or attempt to persuade any employee,
independent contractor, consultant, agent, supplier, licensor, or distributor of
the Company or of any affiliate of the Company to discontinue such person’s
relationship with the Company or the affiliate; (b) hire away or solicit to hire
away from the Company or from any of its affiliates any employee; (c) otherwise
engage or seek to engage any employee or independent contractor of the Company
or of any of its affiliates in a business relationship that would or might
conflict with such employee’s or independent contractor’s obligations to the
Company or affiliate; (d) interfere with the Company’s or any of its affiliates’
relationship with any governmental or business entity, including payor,
supplier, licensor, lender, or contractor of the Company or the affiliate; or
(e) disparage the Company or any of its affiliates or any of the shareholders,
directors, officers, employees, or agents of any of them.

    

    6.2           Cooperation.   During
the term of the Agreement with the Company and for a period of five (5) years
following the termination or expiration of the Agreement, BTI agrees to
cooperate with the Company and its affiliates in connection with any litigation
or investigation involving the Company or any of its affiliates or any of the
shareholders, directors, officers, employees, or agents of any of them and shall
furnish such information and assistance as may be lawfully requested by the
Company.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    7.  
          GENERAL
PROVISIONS

    

    7.1           Indemnification.   The
Company hereby agrees to indemnify and hold harmless BTI and the Officer from
and against any and all losses, claims, damages, expenses and/or liabilities
which may incur arising out of the normal course of business in carrying out the
duties and responsibilities associated with the position of Interim Chief
Executive Officer arising from the Officer’s reliance upon and approved use of
information, reports and data furnished by and representations made by the
Company, with respect to itself, where the Officer in turn distributes and
conveys such information, reports and data to the public in the normal course of
representing the Company.  Such indemnification shall include, but not
be limited to, expenses (including all attorneys’ fees), judgments, and amounts
paid in settlement actually and reasonably incurred by BTI or the Officer in
connection with an action, suit or proceeding brought against the Company, BTI
or the Officer.

    

    7.2           Injunctive
Relief.  BTI acknowledges that the injury that would be
suffered by the Company as a result of a breach of the provisions of this
Agreement would be largely irreparable and that an award of monetary damages to
the Company for such a breach would be an inadequate remedy.  The
Company will have the right, in addition to any other rights it may have
(including the right to damages that the Company may suffer), to obtain
injunctive relief to restrain any breach or threatened breach or otherwise to
specifically enforce any provision of this Agreement, and the Company will not
be obligated to post bond or other security in seeking such
relief.  BTI agrees to request neither bond nor security in connection
with any such injunction.  BTI agrees that if BTI or the Officer
breaches this Agreement, BTI and the Officer shall be liable for any attorney’s
fees and costs incurred by the Company in enforcing its rights under this
Agreement.

    

    7.3           Essential, Independent, and
Surviving Covenants.

    

    (a)           The
parties agree that the covenants in Sections 4, 5, and 6 are essential elements
of this Agreement, and without BTI’s agreement to comply with such covenants,
the Company would not have entered into this Agreement.

    

    (b)           The
covenants in Sections 4, 5, and 6 are independent covenants and the existence of
any claim by BTI or the Officer against the Company under this Agreement or
otherwise will not excuse the breach by BTI or the Officer of any covenant in
Section 4, 5, or 6.

    

    (c)           After
the Agreement is terminated, this Agreement will continue in full force and
effect as is necessary or appropriate to enforce the covenants and agreements of
BTI in Sections 4, 5, and 6.

    

    7.4           Notices.   All
notices and other communications which are required or permitted hereunder shall
be in writing and shall be sufficient if mailed by certified mail, postage
prepaid, and shall be effective three days after such mailing or upon delivery,
whichever is earlier, to the following addresses or such other address as the
appropriate party may advise each other party hereto:

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    If to BTI:

    

    Bronco
Technology, Inc.

    Helen R.
Park, CEO

    PO Box
30

    Huntsville,
TX 77342-0030

    

    If to the Company:

     

    Ira L.
Goldknopf, President

    Power3
Medical Products, Inc.

    3400
Research Forest Drive

    The
Woodlands, TX  77381

    

    7.5           Entire
Agreement.   This Agreement contains the entire agreement
between the parties hereto and supersedes all prior agreements and
understandings, oral or written, between the parties hereto with respect to the
subject matter hereof including, without limitation, the Original
Agreement.

    

    7.6           No Third-Party
Beneficiaries.  This Agreement shall not confer any rights or
remedies upon any person other than the Company, BTI, and their respective
successors and permitted assigns, other than as expressly set forth in this
Agreement.

    

    7.7           Amendments and
Waivers.    Except as set forth in Paragraph 2.1(b)
above, this Agreement may not be modified or amended except by an instrument or
instruments in writing signed by the party against whom enforcement of any such
modification or amendment sought.  Either party hereto may, by an
instrument in writing, waive compliance by the other party with any term or
provision of this Agreement on the part of such other party hereto to be
performed or complied with.  The waiver by any party hereto of a
breach of any term or provision of this Agreement shall not be construed as a
waiver of any subsequent breach.  No delay or failure by either party
in exercising any right under this Agreement, and no partial or single exercise
of that right, shall constitute a waiver of that or any other
right.

    

    7.8           Headings.   The
paragraph headings contained in this Agreement are for reference purposes only
and shall not be deemed to be a part of this Agreement or to control or affect
the meaning or construction of any provision of this Agreement.

    

    7.9           Construction.  The
language used in this Agreement will be deemed to be the language chosen by the
Company and the Officer to express their mutual intent, and no rule of strict
construction shall be applied against either party.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    7.10         Counterparts.  This
Agreement may be executed in two or more counterparts, each of which shall be
deemed an original but all of which together shall constitute one and the same
instrument.

    

    7.11         Severability.    If
any term or provision of this Agreement is held or deemed to be invalid or
unenforceable, in whole or in part, by a court of competent jurisdiction, this
Agreement shall be ineffective to the extent of such invalidity or
unenforceability without rendering invalid or unenforceable the remaining terms
and provisions of this Agreement.

    

    7.12         Expenses and Attorney’s
Fees.   In the event that a dispute arises under this
Agreement that results in litigation or arbitration, the prevailing party, as
determined by the decision of a court or forum of competent and final
jurisdiction, shall be entitled to court costs and reasonable attorney’s
fees.  A court or forum of “final” jurisdiction shall mean a court of
forum from which no appeal may be taken or from whose decree, decision,
judgment, or order no appeal is taken or prosecuted.

    

    7.13         Governing
Law.   This Agreement shall be governed by and construed
in accordance with the laws of the State of Texas, without regard to the
conflict of laws principles thereof.

    

    7.14         Agreement
Preparation.   BTI acknowledges that this Agreement has
been prepared by the Company, and BTI has not relied on any representation made
by the Company’s or its attorneys.  BTI has had the opportunity to
engage an attorney of its choice to review this Agreement on its
behalf.  By signing this Agreement, BTI is hereby certifying that BTI
(a) received a copy of this Agreement for review and study before executing it;
(b) read this Agreement carefully before signing it; (c) had sufficient
opportunity before signing the Agreement to ask any questions BTI had about the
Agreement and received satisfactory answers to all such questions; and (d)
understands BTI’s rights and obligations under the Agreement.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, the parties hereto
have duly executed this Agreement as of the date first written above but to be
effective as of the Effective Date.

    

    
      
        
          
            	 
      	
                    BTI:

                  
	 
      	 
      
	 
      	
                    Bronco
      Technology, Inc.

                  
	 
      	 
      
	 
      	
                    By:

                  	
                    /s/ Helen R. Park

                  
	 
      	 
      	
                     
      Helen R. Park, CEO

                  
	 
      	 
      
	 
      	
                    COMPANY:

                  
	 
      	 
      
	 
      	
                    Power
      3 Medical Products, Inc.

                  
	 
      	 
      
	 
      	
                    By:

                  	
                    /s/ Ira L. Goldknopf

                  
	 
      	 
      	
                     
      Ira L. Goldknopf

                  
	 	 	
                     
      Interim Chairman, President, &
CSO

                  

          

        

      

    

     

    
      
         

      

      
        10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]